Novan Company Profile (NASDAQ:NOVN)

About Novan (NASDAQ:NOVN)

Novan logoNovan, Inc. is a late-stage pharmaceutical company. The Company is engaged in the development and commercialization of therapies using its nitric oxide platform. The Company develops product candidates using its Nitricil technology, which enables the Company to engineer tunable new chemical entities (NCEs). The Company's formulation science enables it to further tune the release of nitric oxide when applied to the skin by using the combinations of inactive ingredients. It is developing SB204 for the treatment of acne vulgaris in Phase III. The Company is developing its product candidate, SB206, for the treatment of external genital and perianal warts in Phase II. It is developing SB208, an investigational topical anti-fungal for the treatment of fungal infections of the skin and nails. It is developing SB204 for the treatment of inflammatory skin diseases. Its pipeline also includes SB414, a topical cream product candidate.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Specialty & Advanced Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:NOVN
  • CUSIP: N/A
  • Web:
  • Market Cap: $86.31 million
  • Outstanding Shares: 15,984,000
Average Prices:
  • 50 Day Moving Avg: $6.31
  • 200 Day Moving Avg: $6.31
  • 52 Week Range: $3.52 - $30.90
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.96
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $768,999.00
  • Price / Sales: 112.24
  • Book Value: $0.74 per share
  • Price / Book: 7.30
  • EBIDTA: ($49,040,000.00)
  • Return on Equity: -194.61%
  • Return on Assets: -99.61%
  • Current Ratio: 1.97%
  • Quick Ratio: 1.97%
  • Average Volume: 117,057 shs.
  • Short Ratio: 1.71

Frequently Asked Questions for Novan (NASDAQ:NOVN)

What is Novan's stock symbol?

Novan trades on the NASDAQ under the ticker symbol "NOVN."

How were Novan's earnings last quarter?

Novan Inc (NASDAQ:NOVN) released its quarterly earnings data on Friday, May, 12th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.49) by $0.24. The business earned $0.10 million during the quarter, compared to analysts' expectations of $10.80 million. View Novan's Earnings History.

When will Novan make its next earnings announcement?

Novan is scheduled to release their next quarterly earnings announcement on Monday, November, 13th 2017. View Earnings Estimates for Novan.

Where is Novan's stock going? Where will Novan's stock price be in 2017?

4 equities research analysts have issued 12 month price targets for Novan's shares. Their forecasts range from $8.00 to $31.00. On average, they expect Novan's share price to reach $17.24 in the next twelve months. View Analyst Ratings for Novan.

Who are some of Novan's key competitors?

Who are Novan's key executives?

Novan's management team includes the folowing people:

  • Robert A. Ingram, Independent Chairman of the Board
  • Nathan Stasko Ph.D., President, Chief Scientific Officer, Director
  • G. Kelly Martin, Interim Chief Executive Officer, Director
  • William L. Hodges CPA, Interim Chief Financial Officer, Princiapl Financial Officer, Principal Accounting Officer
  • Stanley Hollenbach J.D., Senior Vice President - Research and Development
  • Jeff N. Hunter, Vice President - Technical Operations
  • Paula Brown Stafford, Chief Development Officer, Director
  • Brian M Johnson, Chief Commercial Officer
  • W. Kent Geer, Independent Director
  • Robert J. Keegan, Independent Director

When did Novan IPO?

(NOVN) raised $46 million in an IPO on Wednesday, September 21st 2016. The company issued 3,800,000 shares at a price of $11.00-$13.00 per share. Piper Jaffray acted as the underwriter for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who owns Novan stock?

Novan's stock is owned by many different of institutional and retail investors. Top institutional investors include Franklin Resources Inc. (1.99%), Vanguard Group Inc. (1.22%), Prospera Financial Services Inc (0.17%) and Goldman Sachs Group Inc. (0.16%). Company insiders that own Novan stock include John W Palmour, Life Sciences Holdings L Malin and Robert Alexander Ingram. View Institutional Ownership Trends for Novan.

Who sold Novan stock? Who is selling Novan stock?

Novan's stock was sold by a variety of institutional investors in the last quarter, including Prospera Financial Services Inc. View Insider Buying and Selling for Novan.

Who bought Novan stock? Who is buying Novan stock?

Novan's stock was acquired by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc. and Vanguard Group Inc.. Company insiders that have bought Novan stock in the last two years include John W Palmour, Life Sciences Holdings L Malin and Robert Alexander Ingram. View Insider Buying and Selling for Novan.

How do I buy Novan stock?

Shares of Novan can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novan's stock price today?

One share of Novan stock can currently be purchased for approximately $5.40.

MarketBeat Community Rating for Novan (NASDAQ NOVN)
Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  60 (Vote Outperform)
Underperform Votes:  65 (Vote Underperform)
Total Votes:  125
MarketBeat's community ratings are surveys of what our community members think about Novan and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Novan (NASDAQ:NOVN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $17.24 (219.31% upside)

Analysts' Ratings History for Novan (NASDAQ:NOVN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/3/2017Piper Jaffray CompaniesReiterated RatingBuyLowView Rating Details
4/12/2017WedbushReiterated RatingNeutral$8.00HighView Rating Details
10/17/2016Credit Suisse GroupInitiated CoverageOutperform$27.00 -> $18.97N/AView Rating Details
10/17/2016JMP SecuritiesInitiated CoverageOutperform$31.00N/AView Rating Details
(Data available from 9/24/2015 forward)


Earnings History for Novan (NASDAQ:NOVN)
Earnings by Quarter for Novan (NASDAQ:NOVN)
Earnings History by Quarter for Novan (NASDAQ NOVN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/12/2017Q1 2017($0.49)($0.73)$10.80 million$0.10 millionViewN/AView Earnings Details
3/20/2017Q4 16($1.14)($0.82)ViewN/AView Earnings Details
11/14/2016Q3 16($1.40)($5.76)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Novan (NASDAQ:NOVN)
2017 EPS Consensus Estimate: ($1.47)
2018 EPS Consensus Estimate: ($1.26)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.19)($0.19)($0.19)
Q2 20171($0.67)($0.67)($0.67)
Q3 20171($0.32)($0.32)($0.32)
Q4 20171($0.29)($0.29)($0.29)
Q1 20181($0.21)($0.21)($0.21)
Q2 20181($0.27)($0.27)($0.27)
Q3 20181($0.35)($0.35)($0.35)
Q4 20181($0.43)($0.43)($0.43)
(Data provided by Zacks Investment Research)


Dividend History for Novan (NASDAQ:NOVN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Novan (NASDAQ:NOVN)
Insider Ownership Percentage: 10.72%
Institutional Ownership Percentage: 6.05%
Insider Trades by Quarter for Novan (NASDAQ:NOVN)
Institutional Ownership by Quarter for Novan (NASDAQ:NOVN)
Insider Trades by Quarter for Novan (NASDAQ:NOVN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/29/2017Robert Alexander IngramDirectorBuy12,000$4.57$54,840.00View SEC Filing  
8/23/2017John W PalmourDirectorBuy12,000$3.99$47,880.00View SEC Filing  
9/26/2016Life Sciences Holdings L MalinMajor ShareholderBuy800,000$11.00$8,800,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Novan (NASDAQ:NOVN)
Latest Headlines for Novan (NASDAQ:NOVN)
DateHeadline logoNovan Inc (NOVN) Rating Lowered to Strong Sell at ValuEngine - September 22 at 10:10 AM logoNovartis and The Max Foundation transform pioneering cancer access program for people in lower-income countries - September 22 at 9:17 AM logoSupernus Pharmaceuticals (SUPN) versus NOVAN INC (NOVN) Head to Head Analysis - September 21 at 12:32 PM logoNovan Inc (NOVN) Given Average Rating of "Hold" by Analysts - September 21 at 2:34 AM logoNovartis' Xolair® confirms re-treatment efficacy in chronic spontaneous urticaria patients after treatment interruption - September 17 at 5:40 AM logoNovan Inc (NOVN) Rating Increased to Sell at ValuEngine - September 16 at 7:08 PM logoComparing NOVAN INC (NOVN) & Its Competitors - September 13 at 6:20 AM logoAbbVie (ABBV) vs. Novan (NOVN) Critical Review - September 8 at 4:14 PM logoNovartis announces CEO Joseph Jimenez to retire from Novartis in 2018. Vasant Narasimhan appointed CEO, effective February 1, 2018. - September 4 at 1:12 AM logoRobert Alexander Ingram Buys 12,000 Shares of Novan Inc (NOVN) Stock - August 29 at 7:56 PM logoNovan Inc (NOVN) Receives Average Recommendation of "Hold" from Brokerages - August 27 at 2:50 AM logoJohn W. Palmour Acquires 12,000 Shares of Novan Inc (NOVN) Stock - August 25 at 8:34 PM logoNovan (NOVN) Appoints Paula Stafford to Board of Directors - August 17 at 6:15 AM logoQ2 2017 EPS Estimates for Novan Inc (NASDAQ:NOVN) Cut by Wedbush - August 7 at 7:04 AM logoNovan Inc (NASDAQ:NOVN) Receives Average Rating of "Hold" from Brokerages - August 3 at 12:52 AM logoValuEngine Downgrades Novan Inc (NASDAQ:NOVN) to Strong Sell - August 2 at 10:20 PM logoAnalyzing Assembly Biosciences (ASMB) & Novan (NOVN) - August 2 at 12:16 AM logoHead to Head Comparison: Rockwell Medical (RMTI) versus Novan (NASDAQ:NOVN) - August 1 at 10:26 PM logoHead-To-Head Review: DARA Biosciences (DARA) & Novan (NOVN) - August 1 at 8:30 PM logoZacks: Novan Inc (NASDAQ:NOVN) Given Average Recommendation of "Buy" by Analysts - July 31 at 2:26 PM logoEagle Pharmaceuticals (EGRX) versus NOVAN INC (NASDAQ:NOVN) Head-To-Head Comparison - July 29 at 6:08 PM logoNovan Inc (NASDAQ:NOVN) Short Interest Down 26.4% in July - July 29 at 7:14 AM logo Novan Inc (NASDAQ:NOVN) Given $9.50 Average Target Price by Brokerages - July 28 at 8:24 PM logo18 Biggest Mid-Day Gainers For Friday - July 28 at 1:17 PM logo Novan Inc. (NASDAQ:NOVN) Given $9.50 Consensus Target Price by Brokerages - July 24 at 9:56 AM logoCritical Contrast: Aimmune Therapeutics (AIMT) versus Novan (NOVN) - July 22 at 6:29 PM logoTherapeuticsMD (TXMD) and Novan (NASDAQ:NOVN) Financial Review - July 13 at 8:10 AM logo Novan Inc. (NOVN) Receives Consensus Rating of "Buy" from Brokerages - June 22 at 8:14 AM logoNovan Inc (NOVN) Sees Significant Decrease in Short Interest - May 31 at 7:12 AM logoZacks: Novan Inc (NOVN) Given Average Recommendation of "Buy" by Analysts - May 30 at 10:47 PM logoZacks Investment Research Lowers Novan Inc (NOVN) to Hold - May 28 at 8:36 AM logoNovan Inc Expected to Post Q2 2017 Earnings of ($0.57) Per Share (NOVN) - May 17 at 7:46 AM logoZacks: Brokerages Anticipate Novan Inc (NOVN) to Announce -$0.58 Earnings Per Share - May 16 at 2:18 PM logoNovan Inc (NOVN) Posts Earnings Results, Misses Estimates By $0.24 EPS - May 15 at 11:18 AM logoNovan Inc (NOVN) Sees Significant Increase in Short Interest - May 13 at 7:20 AM logoZacks: Analysts Set $9.50 Target Price for Novan Inc (NOVN) - May 6 at 12:34 AM logoNovartis exercises exclusive option agreement with Conatus for the treatment of NASH - May 4 at 11:19 AM logoNovan Presents Preclinical Data from Inflammatory Skin Diseases Program - April 27 at 10:05 AM logoNovan Presents Safety Data for SB204 Program - April 27 at 10:05 AM logoAlcon announces EU launch of CyPass® Micro-Stent, a micro invasive glaucoma surgical device, to lower intraocular pressure (IOP) in patients with primary open-angle glaucoma - April 26 at 6:24 PM logo Novan Inc (NOVN) Receives Consensus Rating of "Buy" from Analysts - April 20 at 8:28 PM logoNovartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients with r/r DLBCL - April 18 at 10:06 AM logoNovan Inc (NOVN) Given a $11.00 Price Target by Piper Jaffray Companies Analysts - April 18 at 7:47 AM logoPre-Open Stock Movers 04/12: (NOVN) (NBIX) (BBRY) Higher; (NS) (ONVO) (TSCO) Lower (more...) - April 13 at 8:14 AM logoNovan Inc (NOVN) Receives "Neutral" Rating from Wedbush - April 12 at 2:01 PM logo11 Biggest Mid-Day Gainers For Wednesday - April 12 at 1:36 PM logo19 Stocks Moving In Wednesday's Pre-Market Session - April 12 at 10:25 AM logoNovan Inc. (NOVN) Is Up Sharply On Phase 2 Study Results - April 12 at 10:25 AM logoNovan Reports Positive Topline Results with SB208 in Phase 2 Trial - April 12 at 10:25 AM logoNovan's stock rockets after positive trial results - April 12 at 10:25 AM



Novan (NOVN) Chart for Sunday, September, 24, 2017

This page was last updated on 9/24/2017 by Staff